این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Research in Pharmaceutical Sciences، جلد ۱۹، شماره ۵، صفحات ۵۰۰-۵۰۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Expression and purification of SARS-CoV-2 receptor binding domain in Escherichia coli for diagnostic and therapeutic purposes
چکیده انگلیسی مقاله Background and purpose: SARS-CoV-2 causes a severe respiratory disease known as COVID-19 and is responsible for a global viral pandemic. The SARS-CoV-2 receptor binding domain (RBD) is located on the spike protein, which identifies and binds to the angiotensin-converting enzyme 2 (ACE2) receptor. The RBD is an important target for developing virus-neutralizing antibodies, vaccines, and   inhibitors. Experimental approach: In this study, recombinant SARS-CoV-2 RBD was expressed in E. coli BL21 (DE3) and purified and its binding activity was determined . Purification was conducted using the Ni-NTA column. ELISA. flow cytometry assays were set to evaluate the binding ability of recombinant RBD to different anti-RBD antibodies and native ACE2 receptors on HEK293A cells, respectively. Findings/Results: The SDS-PAGE analysis revealed the corresponding band at 27 kDa in the culture after induction with 0.7 mM IPTG, while the corresponding band was not observed in the culture without IPTG induction. ELISA results showed that antibodies produced in the human sera could bind to the recombinant RBD protein and the commercial anti-RBD antibody. Also, flow cytometry analysis revealed that the recombinant RBD could bind to human ACE2 on the surface of HEK293A cells. Conclusion and implication: Our outcomes displayed that the recombinant RBD expressed in the E. coli strain has biological activity and can be used as an antigen for the development of diagnosis kits and vaccines as well as a tool for screening drugs against SASR-CoV-2.    
کلیدواژه‌های انگلیسی مقاله Angiotensin-converting enzyme 2,Gene cloning,Purification,Receptor binding domain,Severe-acute respiratory syndrome coronavirus 2.
نویسندگان مقاله | Hajarossadat Ghaderi
Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.


| Alireza Shoari
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran,Tehran, Iran.


| Shima Salehi
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran,Tehran, Iran.


| Ayda Hassanzadeh Eskafi
National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.


| Mahdi Habibi-Anbouhi
Nanobiotechnology Department, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran.


| Reza Ahangari Cohan
Department of Protein Engineering, ReNAP Therapeutics, Tehran, Iran.


| Reza Moazzami
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran,Tehran, Iran. Zoonoses Research Center, Pasteur Institute of Iran, Amol, Iran.


| Mahdi Behdani


نشانی اینترنتی http://rps.mui.ac.ir/index.php/jrps/article/view/2269
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات